Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.39 |
| ▸ | FRK | P42685 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2722016 | 0.96 | MAPK14 (0.41) | MAPK14CYP2C9HSPB1MAPK11EPHA3 | |
| SCHEMBL2722018 | 0.92 | MAPK14 (0.38) | MAPK14CYP2C9HSPB1MAPK11EPHA3 | |
| SCHEMBL2722176 | 0.90 | MAPK14 (0.47) | MAPK14MAPK11RAF1 | |
| SCHEMBL4070901 | 0.89 | MAPK14 (0.42) | MAPK14CYP2C9HSPB1MAPK11EPHA3 | |
| SCHEMBL3536611 | 0.89 | RAF1 (0.37) | MAPK14MAPK11RAF1BRAF | |
| SCHEMBL3536447 | 0.88 | MAPK14 (0.44) | MAPK14MAPK11RAF1 | |
| SCHEMBL3529884 | 0.88 | MAPK14 (0.44) | MAPK14MAPK11RAF1 | |
| SCHEMBL3526090 | 0.88 | MAPT (0.39) | MAPK14RAF1BRAF | |
| SCHEMBL3535843 | 0.87 | RAF1 (0.36) | MAPK14MAPK11RAF1BRAF | |
| SCHEMBL2718133 | 0.87 | MAPK14 (0.41) | MAPK14MAPK11RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678801-B2 | 3-(8-(2,6-Difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl)-4-methyl-N-1,3-thiazol-2-ylbenzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2010-03-16 | — | — | US | claimed |
| EP-2034838-A2 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | claimed |
| WO-2007147103-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| EP-2447266-A1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LIMITED (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20100144755-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20090156597-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156597-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090156597-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-06-18 | — | — | US | disclosed |
| US-20090069318-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069318-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069318-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| WO-2007147103-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144755-A1 | Novel Compounds | MAPKAPK2, CDC42BPB, MAPK8 | MAPK14 35/4885CYP2C9 4861/4885HSPB1 454/4885 |
| US-20090156597-A1 | Novel Compounds | MAPKAPK2, MAPK8, MAPKAPK3 | MAPK14 43/4885CYP2C9 4842/4885HSPB1 595/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | MAPK14 35/4885CYP2C9 4861/4885HSPB1 454/4885 |
| US-20090069318-A1 | Novel Compounds | MAPKAPK2, MAPK8, MAPKAPK3 | MAPK14 43/4885CYP2C9 4842/4885HSPB1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.